WO2025133697 - COMBINATION THERAPY FOR INHIBITION OF EBOLAVIRUS
National phase entry is expected:
Publication Number
WO/2025/133697
Publication Date
26.06.2025
International Application No.
PCT/IB2024/000726
International Filing Date
17.12.2024
Title **
[English]
COMBINATION THERAPY FOR INHIBITION OF EBOLAVIRUS
[French]
POLYTHÉRAPIE POUR L'INHIBITION DE VIRUS EBOLA
Applicants **
REDHILL BIOPHARMA LTD.
Inventors
FATHI, Reza
BEN-ASHER, Dror
GOLDBERG, Guy
Priority Data
63/612,418
20.12.2023
US
63/725,183
26.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3032 | |
| EPO | Filing, Examination, Granting | 20405 | |
| Japan | Filing, Examination, Granting | 2584 | |
| South Korea | Filing, Examination, Granting | 3100 | |
| USA | Filing, Examination, Granting | 7910 |
Total:
37,031
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Combination therapies for the inhibition of single-stranded RNA virus replication, such as ebolaviruses are disclosed herein.[French]
L'invention concerne des polythérapies pour l'inhibition de la réplication de virus à ARN simple brin, tels que des virus Ebola.